Loading
A phase 2 trial of SP-002 run by Ascend Biopharmaceuticals Ltd, completed.
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor is a phase 2 interventional study registered as NCT04416516 by Ascend Biopharmaceuticals Ltd, with 21 participants enrolled, started 2020-07-16. Conditions recorded: Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Interventions recorded: ASN-002.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/